SPRY FY2025 EPS Estimate Lowered by Cantor Fitzgerald

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($1.21) for the year, down from their prior forecast of ($1.02). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million.

Other research analysts have also issued research reports about the stock. Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price on the stock. Oppenheimer began coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target for the company. Raymond James upped their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Finally, William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $31.00.

ARS Pharmaceuticals Price Performance

Shares of SPRY opened at $12.63 on Wednesday. The company’s 50-day moving average is $12.15 and its 200-day moving average is $13.07. The firm has a market capitalization of $1.24 billion, a PE ratio of -24.76 and a beta of 1.03. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

Insider Transactions at ARS Pharmaceuticals

In other news, Director Laura Shawver sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,589,359.26. This represents a 19.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now owns 7,696 shares in the company, valued at $107,744. This represents a 56.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 159,600 shares of company stock valued at $1,866,516. 40.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SPRY. Bernard Wealth Management Corp. bought a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $27,000. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $73,000. BNP Paribas Financial Markets acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at approximately $75,000. Ball & Co Wealth Management Inc. bought a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth $105,000. Finally, Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the 4th quarter worth $106,000. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.